This week has seen the launch of new and lower-priced biosimilars to AbbVie’s Humira (adalimumab), many months after Amgen’s Amjevita (adalimumab-atto) was released in the US in January.

EMA advisors at the Committee for Medicinal Products for Human Use (CHMP) recommended Sandoz’s adalimumab Humira biosimilar under three brand names – Halimatoz, Hefiya and Hyrimoz. The firm ...

Among small-molecule drugs, upadacitinib and deucravacitinib demonstrate the best efficacy for treatment of psoriatic ...

The Department of Veterans Affairs (VA) saved $67 million in 2023 through its strong adoption of biosimilars to curb the high ...

The anti-inflammatory injection, also known as adalimumab, lost its U.S. market ... its dominance with a 96% market share as of February, Humira's market leadership came under threat in 2024 ...

The anti-inflammatory injection, also known as adalimumab, lost its U.S. market ... After accounting for over a third of its revenue in 2022, Humira's contribution to AbbVie's (ABBV) topline ...

For 20 years, AbbVie’s Humira (adalimumab) was one of the world’s top-selling products, but its patent expiry, and the subsequent entry of biosimilars in January 2023 resulted in a 32% decline ...

Image: Adobe Stock To examine the safety and efficacy of switching directly from adalimumab (Humira, AbbVie) to tofacitinib (Xeljanz, Pfizer) in PsA, Gladman and colleagues conducted a post-hoc ...

Humira still dominated 96% of the market as ... notably CVS Health (CVS), kicked it off important formularies.AbbVie has 72% of the adalimumab market as of November 2024; biosimilars are taking ...